Last reviewed · How we verify
NCT03873740
Immunogenicity and Safety of Two Different Commercial EV71 Vaccines
Phase 4 trial testing EV71 inactived vaccine（Vero cells） in Hand, Foot and Mouth Disease in 300 participants. Completed in 23 January 2019.
21 January 2019
Quick facts
| Lead sponsor | Sinovac Biotech Co., Ltd |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 6 November 2018 |
| Primary completion | 21 January 2019 |
| Estimated completion | 23 January 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- EV71 inactived vaccine（Vero cells） — full drug profile →
- EV71 inactived vaccine（Human diploid cells） — full drug profile →
Conditions studied
- Hand, Foot and Mouth Disease — all drugs for Hand, Foot and Mouth Disease →
Sponsor
Sinovac Biotech Co., Ltd — full company profile →
Who can join
Adults 6 Months to 35 Months, any sex, with Hand, Foot and Mouth Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03873740
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hand, Foot and Mouth Disease
Currently open trials in the same condition.
- NCT06146088 — Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine · Phase 4 · recruiting
- NCT06063057 — Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial · Phase 1, PHASE2 · active not recruiting
- NCT06263439 — Surveillance of HFMD in Pediatric Outpatients · recruiting
Other Sinovac Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07418229 — Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine · Phase 1 · not yet recruiting
- NCT07416110 — Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine · Phase 3 · not yet recruiting
- NCT07055295 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
- NCT07055893 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
- NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03873740 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinovac Biotech Co., Ltd
- Last refreshed: 29 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03873740.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing